Rare Disease Deals and GLP-One Advances
Kilder
- Endpoints: Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia
- Insights: LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide - insights.citeline.com
- Fierce Biotech: Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win - Fierce Biotech
- STAT: STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
- STAT: Real-world psilocybin data suggest need for close monitoring - STAT
- Labiotech: BIO-Europe 2026: Expanding the scope at Europe’s leading biotech partnering event
- Endpoints: Exclusive: Third death revealed in China's popular but opaque trials
- Raps: Recon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany must reform drug pricing - RAPS
- Endpoints: Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure
- Pharmtech: Dersimelagon Acquisition Highlights Shift Toward Late-Stage Rare Disease Licensing - PharmTech.com
- Pharmaceutical-technology: LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain - Pharmaceutical Technology
- Endpoints: BioMarin does another small deal to get early-stage bone disease asset
- Bizjournals: BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company - The Business Journals
- Prnewswire: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire
- wikimedia: Photo by U.S. Navy photo by Aleece Williams / Wikimedia Commons / Public domain
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.